ESR1 and breast carcinoma: We would like to make a note that although Adavosertib can effectively decrease the growth of ER+ breast cancer cells that are resistant to antiestrogen and CDK4/6 inhibitors, the anti-proliferative effect of WEE1 inhibition in these cells is compromised when combined with antiestrogens or CDK4/6 inhibitors.